Asia Pacific Oxytocic Pharmaceuticals Market: By Product Type, By Source, Synthetic Oxytocin), By End-User, and by Country Forecast 2021-2032
Report ID:20678
Published Date:Oct 2025
No of Pages:145
Format:
Asia Pacific Oxytocic Pharmaceuticals Market size was valued at US$ 133.2 million in 2025 and is expected to reach US$ 225.3 million by 2032, growing at a significant CAGR of 7.8% from 2026-2032. Oxytocin is a female reproductive hormone secreted in the hypothalamus and released into blood circulation during childbirth to induce the labor and milk production in mothers. It is also used as uterotonic (induce uterine contractions) and reduce the hemorrhage after C-section. Increase in the number of female population in India and China, rise in awareness about the oxytocin usage, and escalation in complicated pregnancies are anticipated to boost the asia pacific oxytocic pharmaceuticals market over the forecast years.
Study Period
2026-2032Base Year
2025CAGR
7.8%Largest Market
N/AFastest Growing Market
N/A
The Adverse effects associated with oxytocic drugs and lack of awareness in underdeveloped countries may restrain the growth of Asia Pacific oxytocic pharmaceuticals market over the forecast period.
Asia Pacific oxytocic pharmaceuticals market is segmented into Japan, China, India, Australia & New Zealand, ASEAN Countries, South Korea, and Rest of Asia Pacific. Japan oxytocic pharmaceuticals market driven by high awareness about oxytocin usage among healthcare professionals. China oxytocic pharmaceuticals market accounted for significant share, which is attributed to large patient pool, alteration to two children policy from single child policy, and increase in prevalence of post-partum hemorrhage. India oxytocic pharmaceuticals marketexpected to present lucrative growth opportunities owing to increase in childbirths, high usage of oxytocin, and rise in number of pre-mature labor cases are boost the market.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2026-2032 |
|
Market CAGR |
7.8% |
|
By Product Type |
|
|
By source |
|
|
By End User |
|
Download Free Sample Report
The asia pacific oxytocic pharmaceuticals market size was valued at US$ 123.52 million in 2024 and is expected to reach US$ 208.96 million by 2031, growing at a significant CAGR of 7.8% from 2025-2031.
Pfizer, Inc., Fresenius Kabi AG, Novartis AG , Cardinal Health , Par Pharmaceutical, Inc.
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Content Updated Date: Jan 2026
| 1.Executive Summary |
| 2.Global Asia Pacific Oxytocic Pharmaceuticals Market Introduction |
| 2.1.Global Asia Pacific Oxytocic Pharmaceuticals Market - Taxonomy |
| 2.2.Global Asia Pacific Oxytocic Pharmaceuticals Market - Definitions |
| 2.2.1.Product Type |
| 2.2.2.source |
| 2.2.3.End User |
| 2.2.4.Country |
| 3.Global Asia Pacific Oxytocic Pharmaceuticals Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Asia Pacific Oxytocic Pharmaceuticals Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Asia Pacific Oxytocic Pharmaceuticals Market By Product Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 5.1. Intramuscular Injection |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Intravenous Injection |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 6.Global Asia Pacific Oxytocic Pharmaceuticals Market By source, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 6.1. Natural Oxytocin (Animal Pituitary Extracts) |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Synthetic Oxytocin |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7.Global Asia Pacific Oxytocic Pharmaceuticals Market By End User, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 7.1. Maternity Clinics |
| 7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Hospitals |
| 7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 8.Global Asia Pacific Oxytocic Pharmaceuticals Market By Country, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 8.1. China |
| 8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. India |
| 8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Australia and New Zealand (ANZ) |
| 8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Japan |
| 8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Rest of APAC |
| 8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9. Competition Landscape |
| 9.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 9.2.1.Pfizer, Inc. |
| 9.2.2.Fresenius Kabi AG |
| 9.2.3.Novartis AG |
| 9.2.4.Cardinal Health |
| 9.2.5.Par Pharmaceutical, Inc. |
| 10. Research Methodology |
| 11. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
